These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28199203)

  • 61. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis.
    Koob GF
    Addiction; 2006 Sep; 101 Suppl 1():23-30. PubMed ID: 16930158
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neurobiology of addiction. Toward the development of new therapies.
    Koob GF
    Ann N Y Acad Sci; 2000; 909():170-85. PubMed ID: 10911930
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of orexin type-1 receptors in paragiganto-coerulear modulation of opioid withdrawal and tolerance: A site specific focus.
    Ahmadi-Soleimani SM; Azizi H; Gompf HS; Semnanian S
    Neuropharmacology; 2017 Nov; 126():25-37. PubMed ID: 28826827
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neural substrates of opiate reinforcement.
    Bozarth MA; Wise RA
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):569-75. PubMed ID: 6320300
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction.
    Blum K; Thanos PK; Oscar-Berman M; Febo M; Baron D; Badgaiyan RD; Gardner E; Demetrovics Z; Fahlke C; Haberstick BC; Dushaj K; Gold MS
    J Reward Defic Syndr; 2015; 1(3):95-104. PubMed ID: 27398406
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
    Blum K; Steinberg B; Gondre-Lewis MC; Baron D; Modestino EJ; Badgaiyan RD; Downs BW; Bagchi D; Brewer R; McLaughlin T; Bowirrat A; Gold M
    Psychol Res Behav Manag; 2021; 14():2115-2134. PubMed ID: 34949945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms.
    Liu TT; Shi J; Epstein DH; Bao YP; Lu L
    Cell Mol Neurobiol; 2009 Jun; 29(4):449-54. PubMed ID: 19109766
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2003; (3):CD003409. PubMed ID: 12917966
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2002; (2):CD003409. PubMed ID: 12076479
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of opiate detoxification in jails.
    Fiscella K; Moore A; Engerman J; Meldrum S
    J Addict Dis; 2005; 24(1):61-71. PubMed ID: 15774411
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
    Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pupillometric changes during gradual opiate detoxification correlate with changes in symptoms of opiate withdrawal as measured by the Weak Opiate Withdrawal Scale.
    Rosse RB; Johri S; Goel M; Rahman F; Jawor KA; Deutsch SI
    Clin Neuropharmacol; 1998; 21(5):312-5. PubMed ID: 9789712
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Alcoholism: allostasis and beyond.
    Koob GF
    Alcohol Clin Exp Res; 2003 Feb; 27(2):232-43. PubMed ID: 12605072
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug dependence: stress and dysregulation of brain reward pathways.
    Kreek MJ; Koob GF
    Drug Alcohol Depend; 1998; 51(1-2):23-47. PubMed ID: 9716928
    [No Abstract]   [Full Text] [Related]  

  • 76. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine.
    Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reduction of opiate withdrawal symptoms with use of clonidine in a county jail.
    Fresquez-Chavez KR; Fogger S
    J Correct Health Care; 2015 Jan; 21(1):27-34. PubMed ID: 25431436
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug-sensitive reward in crayfish: an invertebrate model system for the study of SEEKING, reward, addiction, and withdrawal.
    Huber R; Panksepp JB; Nathaniel T; Alcaro A; Panksepp J
    Neurosci Biobehav Rev; 2011 Oct; 35(9):1847-53. PubMed ID: 21182861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Commentary: The opioid overdose epidemic: Evidence-based interventions.
    Barglow P
    Am J Addict; 2018 Dec; 27(8):605-607. PubMed ID: 30311993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.